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Purpose: Evidence-based guideline recommendations for vancomycin
dosing recently shifted from a trough-based strategy to an area under the
curve (AUC) approach. While several AUC dosing methods exist, the optimal approach has not been determined. Literature characterizing time
requirements for various vancomycin dosing strategies remains limited.
Methods: A time and motion study was conducted to measure the time
spent by clinical pharmacists dosing vancomycin using an AUC nomogram. Pharmacists who dosed and monitored vancomycin for adult patients on the general medical ward (GMW) or intensive care unit (ICU) of
a large academic medical center consented to study participation. Vulnerable patients and vancomycin orders for surgical infection prophylaxis
were excluded. The primary outcome was the median amount of time clinical pharmacists dedicated to vancomycin-related clinical activities during
an 8-hour weekday shift. Secondary outcomes included the proportion of
patients prescribed vancomycin at the beginning of each shift and factors
contributing to greater than average time spent on vancomycin-related
responsibilities.
Results: Seven clinical pharmacists collected data on 178 vancomycin
orders. The estimated amount of time a clinical pharmacist spent on daily
vancomycin responsibilities averaged 10.45 minutes (interquartile range
[IQR], 6.94-15.8 minutes). The overall median time requirement per vancomycin assessment was 3.45 minutes (IQR, 1.95-6.7 minutes). The only factor independently associated with prolonged dosing time was follow-up
dosing from a previous day.
Conclusion: The study elucidated time requirements associated with an
AUC nomogram–based vancomycin dosing approach. This data could be
used to compare time requirements associated with other existing vancomycin dosing strategies, which may help healthcare systems determine
the optimal AUC dosing method for their specific practice model.
Keywords: area under curve, methicillin-resistant Staphylococcus aureus,
pharmacists, pharmacokinetics, time and motion studies, vancomycin
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V

ancomycin is a glycopeptide antibiotic used to treat gram-positive
bacterial infections, most notably
methicillin-resistant
Staphylococcus
aureus (MRSA). It is a commonly used
antibiotic within the hospital setting
and has been linked to increased rates
of bacterial resistance.1,2 The current
AM J HEALTH-SYST PHARM |

vancomycin dosing and monitoring
guidelines recommend an area under
the curve (AUC)–based monitoring
approach over the traditional trough
strategy, with a goal target AUC of 400
to 600 mg/L · h.3 This target range, when
compared with traditional trough goals
of 15 to 20 mg/L, provides equivalent
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Evaluation of pharmacist time dedicated to vancomycin
dosing in adult patients using a 24-hour AUC
nomogram or trough monitoring approach: A time
motion study

Practice Research Report

Methods
This was an institutional review
board–approved time and motion study
performed at an 877-bed academic
medical center located in Detroit, MI,
between December 2019 and March
2020. Since time and motion studies
collect quantitative data regarding the
duration and movements of a specific
task, they’re often utilized to optimize
workflow efficiency.11 At the study institution, physicians and advanced
practice providers prescribe vancomycin. Decentralized clinical pharmacists provide direct patient care on the
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KEY POINTS
• An area under the curve (AUC)
approach is recommended
for vancomycin monitoring,
but the optimal method in
terms of workflow efficiency is
unknown.
• A time-motion study showed
that pharmacists using an
AUC nomogram–based vancomycin dosing guideline each
spent approximately 10 minutes on vancomycin dosing
and monitoring per day.
• Overall, there was low utilization
of the AUC nomogram, primarily
due to a low prevalence of both
documented MRSA infections
and acute kidney injury.

general medical wards (GMWs) and intensive care units (ICUs). Pharmacists
assess appropriateness of vancomycin
therapy and are delegated authority for
vancomycin dosing, monitoring, and
documentation of therapy in the electronic medical record (EMR) based on
an institutional clinical practice guideline. Pharmacists place a pharmacokinetic consultation note in the EMR
for vancomycin therapy initiation, dose
adjustment(s), level assessment(s), and
therapy discontinuation.
A modified Matzke dosing nomogram was used to select the initial
maintenance dose according to actual
body weight and creatinine clearance
(eTables 1 and 2).12 A maximum dose
of 2 g intravenously every 8 hours was
utilized. AUC nomogram–based monitoring is used for empiric treatment
of serious infections in which MRSA
is a possible pathogen or for cultureconfirmed MRSA infections. The
nomogram was adapted from a population based pharmacokinetic study by
Lewis et al10 (eFigure 1). MRSA risk factors include treatment with antibiotics
within 90 days, hospitalization within
90 days, history of MRSA infection,
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immunocompromising
conditions,
severe and/or purulent wound infections, and history of injection drug use.
Examples of serious MRSA infections
include culture-confirmed or suspected MRSA pneumonia, MRSA bacteremia, and MRSA endocarditis.
In patients with gram-positive central nervous system (CNS) infections,
a trough goal of 15 to 20 µg/mL is targeted along with an AUC goal of less
than 700 mg/L · h to mitigate nephrotoxicity risk. Higher trough goals are
used in these patients to ensure adequate vancomycin concentrations
within the CNS. Trough-based monitoring targeting a goal of 8 to 15 µg/mL
and linear kinetics are used for other
scenarios, which include non-MRSA
gram-positive infections, and for suspected or confirmed MRSA infections
without bacteremia or pneumonia
(ie, skin infection and urinary tract
infection).
If acute kidney injury (AKI) is present, vancomycin therapy is dosed
using intermittent doses, with random
sampling of vancomyin levels, for all
infection scenarios. For purposes of
our study, AKI was defined as a serum
creatinine increase of 0.3 mg/dL or 30%
(whichever was greater) or urine output
less than 0.5 mL/kg/h for 6 hours or
more. Renal function was considered
to be at baseline if the patient’s current serum creatinine values were near
a known baseline level, if available.
Stable renal function was defined as
toleration of a scheduled vancomycin
regimen without either AKI or requirement of renal replacement therapy.
Once a vancomycin level is obtained
based on the dosing scenario described
above, the institutional vancomycin
guideline recommends a trough or
AUC monitoring approach based upon
infection source(s), renal function
status, whether or not empiric MRSA
risk factors are present, and whether or
not an MRSA infection is confirmed by
culture.
Pharmacists were eligible for study
inclusion if they had completed a minimum of 1 year of practice after their terminal postgraduate year (PGY) training,
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efficacy with a reduced nephrotoxicity
risk.3 Moreover, evidence suggests traditional trough goals of 15 to 20 mg/L are
not associated with improved patient
outcomes.3-5
Despite the benefits of AUC dosing
strategy for MRSA infections, vancomycin dosing and monitoring can be
a significant time commitment for
pharmacists.6-8 Vancomycin is often
prescribed for nonestablished MRSA
infections and is used inappropriately
in patients without an indication for
MRSA coverage.1,2,9 Therefore, optimizing vancomycin dosing workflow
can improve pharmacist efficiency and
allow for additional patient care activities. Current AUC dosing strategies
include a 2-point pharmacokinetic
trapezoidal method, Bayesian software,
and a nomogram-based approach.3
Ensuring appropriate vancomycin
utilization and dose optimization in
practice, however, can contribute to
greater time, financial, and workload
requirements. A large academic medical center underwent a change in its
vancomycin dosing protocol on August
1, 2019, shifting from a trough strategy
to a population-based pharmacokinetic nomogram approach correlating vancomycin dose (in mg/kg)
and trough level to expected AUC.10
The purpose of the study described
here was to assess the amount of time
that a clinical pharmacist dedicates to
vancomycin-related clinical activities
during an 8-hour weekday shift while
using an AUC nomogram approach.

PHARMACIST TIME REQUIREMENTS FOR VANCOMYCIN DOSING

PHARMACIST TIME REQUIREMENTS FOR VANCOMYCIN DOSING

self-captured their own daily vancomycin order time requirements using
standardized stopwatches on cellphones. Standardization of the cellphone stopwatches was performed by
the primary investigator to ensure more
reliable outcomes.11 The primary investigator standardized the stopwatches
by comparing each of the study pharmacists’ phones with a control device
to ensure the phones all accurately recorded time. From that moment, each
of the study pharmacists self-timed
themselves. The time data captured included time required for vancomycin
dosing, monitoring of therapy, medical
record review, and additional responsibilities associated with vancomycin
orders. Additional vancomycin-related
responsibilities included time required to speak with a provider or other
staff regarding vancomycin clarification and/or recommendations. Each
pharmacist initiated their stopwatch
upon entering a patient chart and reviewing the vancomycin order. After
timer initiation, each pharmacist hid
the stopwatch screen by turning their
phone over. Upon order completion,
pharmacists returned their phones to
face-up position, stopped the timer,
and documented the time requirement in a standardized data collection
form. Interruptions and time spent
on unrelated activities were excluded
by pausing the timer during these
situations.
Prior to the active data collection
phase, a 7-day data washout period
took place for each study pharmacist.
Washout period data were excluded
from the study. All vancomycin orders
included in the results were randomized and equally distributed amongst
participating pharmacists until there
were no additional orders remaining.
To validate the accuracy of the stopwatch method, EMR consult note times
were used as time surrogate markers.
Time notations for generating and finalizing a note were abstracted specifically
for new and preexisting vancomycin
orders that required a vancomycin level
assessment. These note completion
times were compared with pharmacist

self-timed data. The primary investigator trained the study pharmacists to
integrate the consult note process into
the self-timing methodology.
Study pharmacists were responsible for collecting data on vancomycin
dosing weight, dosing strategy used,
therapeutic target, volume of distribution assessment, day of therapy, and
ordering of vancomycin levels. The
primary investigator was responsible
for collecting all baseline patient and
infection characteristics, in addition to
AUC utilization rate.
Continuous data were analyzed
using measures of central tendency
depending on whether the data
were parametric or nonparametric.
Categorical data were described using
a chi-square test, while all continuous
data were described using a 2-sample t
test. A bivariate regression analysis was
performed to determine factors which
contributed to prolonged vancomycin
dosing time. A multivariable analysis
was performed to determine factors
that contributed to prolonged dosing
time, which was defined by comparing
the time requirements of the 75th percentile and the top quartile. Variables
were considered for inclusion in the regression model based on a significance
level of P < 0.2 in bivariate analysis and
on clinical rationale. No formal power
calculation was performed, but a conveyance sample of a 1-month time
period for each included pharmacist
was used. Statistical significance was
defined as a P value of <0.05. Data
analysis was performed using SPSS
Statistics for Windows, Version 25 (IBM
Corporation, Armonk, NY).

Results
Seven clinical pharmacists provided consent and were included in
the study (4 GMW and 3 ICU pharmacists). There were 2 male and 5 female
pharmacists. All the included pharmacists were PGY1 residency trained and
Board of Pharmacy Specialties certified. Three pharmacists were also PGY2
residency trained. The median time
in practice post residency was 4 years
(range, 2-8 years). The median daily
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practiced on a GMW or ICU at the study
institution during a weekday dayshift
(7:00 am-3:30 pm), and provided consent
for study participation. Pharmacists recorded the time requirements to complete vancomycin orders that took place
during a weekday, day shift. Vancomycin
orders not included in the study results
were those for patients who were pregnant, were incarcerated, received vancomycin for surgical infection prophylaxis,
orders placed outside of a weekday
dayshift, orders completed by pharmacy
trainees, and orders placed in the emergency room, labor and delivery unit, or
operating room.
The primary outcome was the median time that a study pharmacist spent
on vancomycin-related clinical activities on an 8-hour weekday shift while
using the updated institutional AUC
nomogram approach. This was calculated by measuring the total time spent
on vancomycin-related clinical activities per study day per pharmacist.
All individual pharmacist study days
involving time spent on vancomycinrelated activities were then added
together and divided by the total
pharmacist study days. Study days with
no qualifying vancomycin orders were
excluded from the primary outcome.
Secondary outcomes included the proportion of vancomycin-treated patients
at the beginning and end of each clinical shift, study pharmacists’ median
daily patient census, and factors that
contributed to greater than average
time spent on vancomycin responsibilities. Each vancomycin consultation
was classified as new start therapy
or follow-up on an existing order. All
endpoints were compared between
GMW and ICU patients. Documented
resistant infections were defined as
those for which microbiological culture
data were positive for either MRSA or
a vancomycin-resistant enterococcus.
Chronic kidney disease (CKD) was
defined as a creatinine clearance of
≤60 mL/min without evidence of AKI.
At study initiation, the study pharmacists underwent training to standardize the data collection method.
Study pharmacists self-timed and

Practice Research Report

Practice Research Report

PHARMACIST TIME REQUIREMENTS FOR VANCOMYCIN DOSING

P < 0.05). Additional pharmacist vancomycin consult/workload characteristics are represented in Table 1. Overall,

Table 1. Vancomycin Order Characteristicsa
GMW orders

ICU orders

Overall

n = 48

n = 38

n = 86

Vancomycin orders at beginning of shift, median (IQR)

2.5 (1-4)

4 (3-5)

3 (1.25-4.75)

0.026

Patients at beginning of shift, median (IQR)

42.5 (39-48)

18 (18-20)

34.5 (19-43)

<0.001

Vancomycin orders at end of shift, median (IQR)

2 (1-4)

3.5(2-4)

3 (1-4)

0.022

Patients at end of shift, median (IQR)

42 (37-46)

18 (18-20)

35 (19-42)

<0.001

Dosing strategy, No. (%)

n = 85

n = 93

n = 178

New initiation of vancomycin

11 (12.9)

10 (10.8)

21 (11.8)

0.651

Nomogram

5 (5.9)

1 (1.1)

6 (3.4)

0.105

2 (2.4)

3 (3.2)

5 (2.8)

>0.999

3 (3.5)

3 (3.2)

6 (3.4)

>0.999

Previous PK/kinetics used

1 (1.2)

2 (2.2)

3 (1.7)

>0.999

Therapy discontinued

Workload characteristics
b

b
b

b

Dose per levels
Intermittent hemodialysis
c

P value

0 (0)

1 (1.1)

1 (0.6)

>0.999

Follow-up day of therapy

74(87.1)

83 (89.2)

157 (88.2)

0.651

Order characteristics, No. (%)

n = 25

n = 36

n = 61

Vancomycin level within therapeutic range

11 (44)

22 (61.1)

33 (54.1)

0.187

AUC utilization rate

3 (12)

5 (13.9)

8 (13.1)

0.723

Infection source, No. (%)

n = 85

n = 93

n = 178

Respiratory

14 (16.5)

70 (75.3)

84 (47.2)

<0.001

SSTIa

34 (40)

11 (11.8)

45 (25.3)

<0.001

Otherd

18 (21.2)

13 (14)

31 (17.4)

0.206

Intraabdominal

18 (21.2)

13 (14)

31 (17.4)

0.206

Bacteremia and/or endocarditis

14 (16.5)

15(16.1)

29 (16.3)

0.951

GU

5 (5.9)

13 (14)

18 (10.1)

0.074

Bone and joint

15 (17.6)

2 (2.2)

17 (9.6)

<0.001

CNS

0 (0)

5 (5.4)

5 (2.8)

0.060

Resistance attributes, No. (%)

n = 85

n = 93

n = 178

Documented resistant infectione

11 (12.9)

14 (15.1)

25 (14)

0.685

Documented resistant infection

11 (12.9)

14 (15.1)

25 (14)

0.685

MRSA risk factor

75 (88.2)

81 (87.1)

156 (87.6)

0.818

29 (34.1)

32 (34.4)

61 (34.3)

0.967

b

b

e

f

Enterococcus risk factor

g

Abbreviations: AUC, area under the curve; CNS, central nervous system; GMW, general medical ward; GU, genitourinary; ICU, intensive care unit;
OSH, outside hospital; PK, pharmacokinetics SSTI, skin and soft tissue infection.
a
Values for n are number of vancomycin orders/consults.
b
Statistically significant difference (P < 0.05) for comparison of GMW vs ICU.
c
Use of a regimen previously used to attain therapeutic levels. This dosing did not necessarily follow the nomogram empiric recommendations.
d
Unknown infectious source or fever of unknown origin.
e
Documented microbiological culture data positive for either MRSA or vancomycin-resistant enterococcus.
f
Antibiotic therapy within 90 days, inpatient hospitalization within 90 days, history of MRSA infection, immunocompromising conditions, severe and/
or purulent wound infections, and history of injection drug use.
g
Previous enterococcal infection, benign prostatic hyperplasia in men with urinary tract infection, structural abnormalities of the urinary tract, or
immunosuppressive agent use.
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daily patient census was significantly greater than ICU pharmacists’
(42.5 [IQR, 39-48] vs 18 [IQR, 18-20],

patient workload for a clinical pharmacist was 34.5 (interquartile range [IQR],
19-43) patients. GMW pharmacists’

PHARMACIST TIME REQUIREMENTS FOR VANCOMYCIN DOSING

indication in the GMW (41.2%). There
was no significant difference in the incidence of MRSA risk factors between the
GMW and ICU cohorts (88.2% vs 87.1%,
P = 0.818), with low rates of documented MRSA positive cultures in both
groups (10.6% and 11.8%, respectively).
For the primary outcome, the median pharmacist time dedicated to
vancomycin-related clinical activities
per weekday clinical day shift was
10.45 minutes (IQR, 6.94-15.8 minutes). There was a minimal difference
in median time requirement between
the GMW (11.0 [IQR, 6.74-15.30] minutes) and ICU (9.40 [IQR, 6.98-15.92]
minutes) pharmacists. The overall
median time requirement per vancomycin assessment was 3.45 minutes
(IQR, 1.95-6.7 minutes). There were
no significant differences in median
time requirements documented by
the GMW and ICU pharmacists (3.45
minutes [IQR, 1.l94-7.76 minutes] vs
3.53 minutes [IQR, 2.02-6-21 minutes],
P = 0.811). Vancomycin consults that
included AUC-based monitoring required a greater amount of time per
patient (median, 6.2 minutes [IQR,
3.24-9.55 minutes] vs 3.48 minutes
[IQR, 1.95-6.83 minutes]; P = 0.162).
Additional findings are represented in
Figure 1. Analysis of EMR consult note

validation times revealed no significant
differences from self-recorded times.
For patients prescribed vancomycin
for whom an EMR note was placed, the
GMW pharmacists’ self-timing resulted
in a median validation time of 8.1 minutes (IQR, 6.3-10.1 minutes), while the
note time stamps indicated a median
of 7 minutes (IQR, 6-9 minutes). Within
the ICU pharmacist group, self-timing
resulted in a median of 5.7 minutes
(IQR, 3.8-8.2 minutes), while note time
stamps showed a median of 5 minutes
(IQR, 4-8 minutes).
While many characteristics were
tested in the bivariate analysis, only
follow-up dosing orders were significantly correlated with prolonged dosing
time (P = 0.002). Variables included in
the multivariable regression analysis
were dosing strategy, new versus continued therapy, infection source, and
hospital location. After adjustment for
AUC dosing and patients with other infections, follow-up dosing was an independent predictor of prolonged dosing
time (P = 0.002).

Discussion
While previously published studies
aimed to better understand the benefits of an AUC dosing strategy versus
a trough strategy, time assessments

Table 2. Patient Characteristics
Characteristica

GMW orders (n = 85)

ICU orders (n = 93)

Overall (n = 178)

P value

Age, median (IQR), y

63 (51-70)

60 (49.5-68.5)

62 (51-69)

0.130

Male, No. (%)

52 (61.2)

40 (43)

92 (51.7)

Actual body weight, median (IQR), kg

83.5 (69.65-102.7)

72.6 (60.25-99.2)

79.9 (63.8-100)

0.109

Stable at baselineb

58 (68.2)

37 (39.8)

95 (53.4)

<0.001

AKIb

11 (12.9)

34 (36.6)

45 (25.3)

<0.001

CKDc

0 (0)

2 (2.2)

2 (1.1)

0.498

CRRT

0 (0)

2 (2.2)

2 (1.1)

0.498

iHD

13 (15.3)

18 (19.4)

31 (17.4)

0.476

PD

3 (3.5)

0 (0)

3 (1.7)

0.107

b

Renal function, No. (%)

Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; CRRT, continuous renal replacement therapy; GMW, general medical ward;
iHD, intermittent hemodialysis; ICU, intensive care unit; PD, peritoneal dialysis.
a
Data for No. (%) are for number (percentage) of patients or orders.
b
Statistically significant difference for comparison of GMW vs ICU (P < 0.05).
c
Creatinine clearance of ≤60 mL/min without evidence of acute injury.
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8.7% of patients cared for by the study
pharmacists during the study period
had an active vancomycin order.
A total of 178 vancomycin orders
were included in the study. Four pharmacists contributed 28 vancomycin
orders each, while the remaining 3
pharmacists contributed 21, 18, and 3
orders, respectively. Of the 178 orders,
85 were for GMW patients and 93 were
for ICU patients. The difference in the
mean ages of GMW and ICU patients
was statistically significant (63 [13] years
vs 60 [13] years, P = 0.005). Compared
with ICU patients, GMW patients had
a higher proportion of male patients
(61.2% vs 43%, P = 0.015) and a higher
incidence of stable renal function at
baseline (68.2% vs 41.9%). Additional
baseline patient characteristics, infection characteristics, and resistance attributes can be found in Table 2. The
incidence of both AKI and intermittent
hemodialysis was greater in ICU patients. Most vancomycin orders evaluated by pharmacists were follow-ups
on existing orders, in both the GMW
and ICU settings (57.6% and 89.2% of
orders, respectively). Respiratory infections were the predominant indication
for vancomycin use in the ICU (74.2% of
orders), while skin and soft tissue infections (SSTIs) were the most common

Practice Research Report

Practice Research Report

PHARMACIST TIME REQUIREMENTS FOR VANCOMYCIN DOSING

Figure 1. Average time requirements per vancomycin order. Outlier time values
in the intensive care unit (ICU) included values of 24.41, 15.56, and 14.88 minutes. GMW indicates general medical ward.
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has never been a direct comparison
of the available strategies. There are a
limited number of published studies
that assess the time involved with
vancomycin dosing and safety monitoring.6 It is unclear if the precision of
a Bayesian model AUC estimate correlates with improved outcomes compared to other, less labor-intensive
approaches to achieving lower overall
vancomycin doses. A prospective study
showed cost savings with the Bayesian
software approach.13 The software,
however, was possibly unaffordable
for smaller institutions that had lower
vancomycin use.14 Advantages of the
Bayesian software include adaptive,
fast predictions; moreover, it doesn’t
require that a patient be at steady state
for assessment, unlike trapezoidal
model and other first-order equation–based models.15,16 Because the
trapezoidal model uses 2 steady-state
vancomycin plasma levels and calculates pharmacokinetic parameters on
the basis of those static variables, it
can be impractical in some settings.13
Examples may include institutions with
a limited number of laboratory sample
runs per day, with limited phlebotomy
and laboratory staffing, or where there
are delays in properly obtaining both
levels. Acute physiologic changes can
also be difficult to account for with
this method, and AUC values may be
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Conclusion
To the authors’ knowledge, this
study represents the first assessment
of a population-based AUC nomogram approach to determining the

Downloaded from https://academic.oup.com/ajhp/advance-article/doi/10.1093/ajhp/zxac094/6566201 by Henry Ford Hospital - Sladen Library user on 13 May 2022

were often underrepresented.3,6 This
study was performed to improve
understanding in this area. A clinical
pharmacist at the study institution
spent a median time of 10.45 minutes per day on vancomycin orders
during an 8-hour weekday shift. When
extrapolated to a 40-hour weekday
dayshift work schedule over 52 weeks,
these results indicate that pharmacists
using the described AUC nomogram
strategy would each spend approximately 45 hours on vancomycinrelated clinical activities yearly. There
were low rates of AUC monitoring in
both the GMW and ICU settings (12%
and 13.9%, respectively), likely due to
the low prevalence of confirmed serious MRSA infections and high rates of
AKI observed in the study population.
There was likely an underestimation
of daily vancomycin time responsibilities, which we believe was primarily
due to excluding afternoon/midnight/
weekend orders, vancomycin ordering
for perioperative prophylaxis, and
processing of vancomycin orders by
trainees.
The aforementioned consensus
guidelines3 give preference to a 2-point
pharmacokinetic trapezoidal model
or Bayesian software approaches to
vancomycin AUC monitoring. This is
because the AUC nomogram approach
is not patient specific. However, there

underestimated relative to Bayesian
estimates.15,16
The time requirements demonstrated in this study, with use of the
AUC nomogram method described, are
arguably noninvasive in terms of pharmacists’ overall daily responsibilities;
thus, the method could be considered
an efficient approach to vancomycin
dosing. It is worth noting that when
AUC monitoring was required, the
median time spent per patient nearly
doubled (from 3.48 to 6.2 minutes).
While vancomycin is often prescribed
for nonestablished MRSA infections,
time contribution towards unnecessary
vancomycin therapy was minimal, with
only approximately 11% of patients
having a documented serious MRSA infection. This additional time allows for
pharmacists to focus on other patientfocused interventions, which include
antimicrobial stewardship, transitions
of care, patient education, and other
clinical responsibilities.
There were several limitations to
this study. Self-reporting and measurement bias may have occurred, because
each pharmacist recorded their own
findings. This method is commonplace
in time and motion studies.17,18 To mitigate these forms of bias in the study, all
stopwatch processes and devices were
standardized, standardized training
took place prior to data collection, a
7-day washout phase was included to
allow study pharmacists to become
proficient in the time and motion
methods, and clinical chart note times
were used as surrogate time markers.11
Note times were not significantly different from study pharmacists’ selftiming values, and the numbers of
observations and studied individuals in
the study were higher than those documented in previous healthcare time
and motion studies.10,17,18 Patient outcomes, including efficacy and safety,
were not evaluated in the study.
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time dedicated to vancomycin-related
clinical services. Clinical pharmacists
spent approximately 10 minutes per
day performing activities related to
vancomycin dosing. Future research
is needed to evaluate the time and financial requirements of various AUCbased vancomycin dosing strategies.
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